(2Z)-2-[hydroxy-[4-(trifluoromethyl)anilino]methylidene]-3-oxobutanenitrile

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2Z)-2-[hydroxy-[4-(trifluoromethyl)anilino]methylidene]-3-oxobutanenitrile
• 化学式: C₁₂H₉F₃N₂O₂
• 分子量: 270.21
• InChiKey: SVEAYFSEBQSZJU-KHPPLWFESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  73.1
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Amino derivatives for the treatment of proliferative skin disorders
  申请人：Almirall, S.A.

  公开号：EP2444088A1

  公开（公告）日：2012-04-25

  Compositions comprising specific amino derivatives for their use in treating proliferative skin diseases or disorders and the use of specific amino derivatives in such a treatment is disclosed.

  本发明公开了包含特定氨基衍生物的组合物，用于治疗增生性皮肤疾病或疾病的用途，并公开了在此类治疗中使用特定氨基衍生物的方法。
• Combinations comprising DHODH inhibitors and COX inhibitors
  申请人：Almirall, S.A.

  公开号：EP2444086A1

  公开（公告）日：2012-04-25

  Combinations comprising (a) DHODH inhibitors and (b) COX inhibitors and their use in treating skin diseases or disorders are disclosed.

  本研究公开了由(a) DHODH 抑制剂和(b) COX 抑制剂组成的组合物及其在治疗皮肤疾病或失调中的用途。
• COMPOUND FOR REGULATING GENE EDITING EFFICIENCY AND APPLICATION THEREOF
  申请人：Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences

  公开号：EP3825409A1

  公开（公告）日：2021-05-26

  A compound for improving the gene editing specificity and application thereof. Specifically disclosed is a compound represented by formula I or a use of a pharmaceutically acceptable salt thereof. The compound and the pharmaceutically acceptable salt thereof are used for preparing an inhibitor, a composition, or a formulation for inhibiting gene editing and/or improving the gene editing specificity. The structure of the formula I is as stated in the description. The compound can significantly improve the accuracy of CRISPR gene editing, thereby providing a simple and high-efficient policy for accurate gene editing.

  一种用于提高基因编辑特异性的化合物及其应用。具体公开了一种由式 I 代表的化合物或其药学上可接受的盐的用途。该化合物及其药学上可接受的盐用于制备抑制基因编辑和/或提高基因编辑特异性的抑制剂、组合物或制剂。式 I 的结构如说明书所述。该化合物可显著提高 CRISPR 基因编辑的准确性，从而为准确的基因编辑提供一种简单高效的策略。
• Combinatorial therapies of neurological disorders
  申请人：PHARNEXT

  公开号：US10799499B2

  公开（公告）日：2020-10-13

  The present invention relates to combinations and methods for the treatment of neurological disorders related Amyloid beta toxicity and/or neuronal death. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease, Alzheimer's disease related disorders, Parkinson's disease, Lewy body dementia, multiple system atrophy and other related synucleinopathies, Huntington's disease, peripheral neuropathies, alcoholism or alcohol withdrawal, neurological manifestations of drug abuse or drug abuse withdrawal, amyotrophic lateral sclerosis, multiple sclerosis, spinal cord injury, epilepsy, traumatic brain injury or brain ischemic events based on 3-phenylsulfonyl-8-(piperazin-1-yl) quinoline and baclofen and/or acamprosate.

  本发明涉及治疗与淀粉样蛋白β毒性和/或神经元死亡相关的神经系统疾病的组合物和方法。更具体地说，本发明涉及治疗阿尔茨海默病、阿尔茨海默病相关疾病、帕金森病、路易体痴呆、多系统萎缩和其他相关的突触核蛋白病、亨廷顿病、周围神经病、酗酒或戒酒、药物滥用或药物滥用的神经系统表现的新型组合疗法、以 3-苯磺酰基-8-(哌嗪-1-基)喹啉和巴氯芬和/或阿坎酸为基础的酗酒或戒酒、药物滥用或药物滥用戒断的神经系统表现、肌萎缩侧索硬化症、多发性硬化症、脊髓损伤、癫痫、脑外伤或脑缺血事件。
• Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
  申请人：PHARNEXT

  公开号：US10905672B2

  公开（公告）日：2021-02-02

  The present invention relates to combinations and methods for the treatment of neurological disorders related to amyloid beta toxicity and/or neuronal death and/or glucose-impaired neuronal metabolism. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease, Alzheimer's disease-related disorders, frontotemporal dementia, Parkinson's disease, Lewy body dementia, Huntington's disease, peripheral neuropathies, alcoholism or alcohol withdrawal, neurological manifestations of drug abuse or drug abuse withdrawal, amyotrophic lateral sclerosis, multiple sclerosis, spinal cord injury, epilepsy, traumatic brain injury or brain ischemic events based on baclofen, acamprosate and at least one medium chain triglyceride.

  本发明涉及治疗与淀粉样蛋白β毒性和/或神经元死亡和/或葡萄糖受损的神经元代谢有关的神经系统疾病的组合和方法。更具体地说，本发明涉及阿尔茨海默病、阿尔茨海默病相关疾病、额颞叶痴呆、帕金森病、路易体痴呆、亨廷顿病、周围神经病、酗酒或戒酒的新型组合疗法、基于巴氯芬、阿坎酸和至少一种中链甘油三酯的神经系统表现或药物滥用戒断、肌萎缩性脊髓侧索硬化症、多发性硬化症、脊髓损伤、癫痫、脑外伤或脑缺血事件。